Division of Pulmonology, Department of Internal Medicine, Faculty of Medicine University of Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
Acta Med Indones. 2022 Apr;54(2):266-282.
There is a stigma that ultrasound cannot be used to see abnormalities in the air-filled organs makes ultrasound rarely used to identify lung abnormalities. This study purpose comparing diagnostic accuracy of BLUE protocol with gold standard for each diagnosis causing acute respiratory failure.
Systematic search was done in 6 databases (Pubmed/MEDLINE, Embase, Cochrane Central, Scopus, Ebscohost/CINAHL dan Proquest) and multiple grey-literature sources for cross-sectional studies. We manually extracted the data from eligible studies and calculated pooled sensitivity, pooled specificity, likelihood ratio (LR) and diagnostic odds ratio (DOR). We follow PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guideline throughout these processes.
Four studies has been picked from total 509 studies involved. The results yield parameters indicating BLUE protocol as a reliable modality to diagnose pneumonia with pooled sensitivity 84% (95% CI, 76-89%), pooled specificity 98% (95% CI, 93-99%), LR+ 42 (95% CI, 12-147), LR- 0.12 (95% CI, 0.07-0.2) and DOR 252 (95% CI, 81-788), respectively. It also considerably applicable to diagnose pulmonary oedema with pooled sensitivity 89% (95% CI, 81-93%), pooled specificity 94% (95% CI, 89-96%), LR+ 14 (95% CI, 8-25), LR- 0.165 (95% CI, 0.11-0.24), and DOR 116 (95% CI, 42-320), respectively.
BLUE protocol has good diagnostic accuracy to diagnose pneumonia and pulmonary oedema. We recommend implementing BLUE protocol as a tool in evaluating cause of ARF.
有一种观念认为,超声无法用于检查充满空气的器官的异常,这使得超声很少用于识别肺部异常。本研究旨在比较 BLUE 方案与导致急性呼吸衰竭的每种诊断标准的金标准的诊断准确性。
我们在 6 个数据库(PubMed/MEDLINE、Embase、Cochrane Central、Scopus、Ebscohost/CINAHL 和 Proquest)和多个灰色文献来源中进行了系统搜索,以寻找横断面研究。我们从合格研究中手动提取数据,并计算了合并敏感性、合并特异性、似然比 (LR) 和诊断比值比 (DOR)。我们在整个过程中遵循 PRISMA(系统评价和荟萃分析的首选报告项目)指南。
从总共涉及的 509 项研究中筛选出 4 项研究。结果得出的参数表明,BLUE 方案是一种可靠的诊断肺炎的方法,其合并敏感性为 84%(95% CI,76-89%),合并特异性为 98%(95% CI,93-99%),LR+为 42(95% CI,12-147),LR-为 0.12(95% CI,0.07-0.2),DOR 为 252(95% CI,81-788)。它也可相当适用于诊断肺水肿,合并敏感性为 89%(95% CI,81-93%),合并特异性为 94%(95% CI,89-96%),LR+为 14(95% CI,8-25),LR-为 0.165(95% CI,0.11-0.24),DOR 为 116(95% CI,42-320)。
BLUE 方案对诊断肺炎和肺水肿具有良好的诊断准确性。我们建议将 BLUE 方案作为评估急性呼吸衰竭病因的一种工具加以实施。